Efficacy and safety of dapagliflozin on kidney and cardiovascular outcomes by baseline albuminuria: a secondary analysis of the DAPA-CKD trial

被引：0
|
作者：
Heerspink, H. J. Lambers [1 ]
Waijer, S. W. [1 ]
Vart, P. [1 ]
Cherney, D. Z. I. [2 ]
Chertow, G. [3 ]
Langkilde, A. M. [4 ]
McMurray, J. J. V. [5 ]
Rossing, P. [6 ]
Correa-Rotter, R. [7 ]
Stefansson, B. V. [4 ]
Toto, R. [8 ]
Wheeler, D. [9 ]
机构：
[1] Univ Med Ctr Groningen, Groningen, Netherlands
[2] Univ Toronto, Toronto, ON, Canada
[3] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[4] AstraZeneca, Gothenburg, Sweden
[5] Univ Glasgow, Glasgow, Lanark, Scotland
[6] Steno Diabet Ctr, Copenhagen, Denmark
[7] Natl Med Sci & Nutr Inst Salvador Zubiran, Mexico City, DF, Mexico
[8] UCL, Dept Internal Med, London, England
[9] UCL, Dept Renal Med, London, England
来源：
DIABETOLOGIA | 2021年 / 64卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
51
引用
收藏
页码：30 / 30
页数：1
相关论文
共 50 条
  • [21] Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
    Heerspink, Hiddo J. L.
    Stefansson, Bergur, V
    Chertow, Glenn M.
    Correa-Rotter, Ricardo
    Greene, Tom
    Hou, Fan-Fan
    Lindberg, Magnus
    McMurray, John
    Rossing, Peter
    Toto, Roberto
    Langkilde, Anna Maria
    Wheeler, David C.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 (02) : 274 - 282
  • [22] Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial
    Marx, Nikolaus
    Floege, Juergen
    EUROPEAN HEART JOURNAL, 2021, 42 (13) : 1228 - 1230
  • [23] Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease: A Post Hoc Analysis of DAPA-CKD
    Schechter, Meir
    Jongs, Niels
    Chertow, Glenn M.
    Mosenzon, Ofri
    McMurray, John J., V
    Correa-Rotter, Ricardo
    Rossing, Peter
    Langkilde, Anna Maria
    Sjostrom, C. David
    Toto, Robert D.
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (01) : 59 - +
  • [24] Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria A CREDENCE Secondary Analysis
    Jardine, Meg
    Zhou, Zien
    Heerspink, Hiddo J. Lambers
    Hockham, Carinna
    Li, Qiang
    Agarwal, Rajiv
    Bakris, George L.
    Cannon, Christopher P.
    Charytan, David M.
    Greene, Tom
    Levin, Adeera
    Li, Jing-Wei
    Neuen, Brendon L.
    Neal, Bruce
    Oh, Richard
    Oshima, Megumi
    Pollock, Carol
    Wheeler, David C.
    de Zeeuw, Dick
    Zhang, Hong
    Zinman, Bernard
    Mahaffey, Kenneth W.
    Perkovic, Vlado
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 16 (03): : 384 - 395
  • [25] Effects of Dapagliflozin in Patients Without Diabetes and Microalbuminuria: An Exploratory Analysis From the DAPA-CKD Trial
    Heerspink, Hiddo J. L.
    Chertow, Glenn
    Jongs, Niels
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, David
    Langkilde, Anna Maria
    Wheeler, David C.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 847 - 848
  • [26] Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial
    Tuttle, Katherine R.
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (11): : 727 - 728
  • [27] Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
    Wheeler, David C.
    Stefansson, Bergur, V
    Jongs, Niels
    Chertow, Glenn M.
    Greene, Tom
    Hou, Fan Fan
    McMurray, John J., V
    Correa-Rotter, Ricardo
    Rossing, Peter
    Toto, Robert D.
    Sjostrom, C. David
    Langkilde, Anna Maria
    Heerspink, Hiddo J. L.
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (01): : 22 - 31
  • [28] A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function
    Heerspink, Hiddo J. L.
    Cherney, David
    Postmus, Douwe
    Stefansson, Bergur, V
    Chertow, Glenn M.
    Dwyer, Jamie P.
    Greene, Tom
    Kosiborod, Mikhail
    Langkilde, Anna Maria
    McMurray, John J., V
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, C. David
    Toto, Robert D.
    Wheeler, David C.
    KIDNEY INTERNATIONAL, 2022, 101 (01) : 174 - 184
  • [29] A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
    Wheeler, David C.
    Toto, Robert D.
    Stefansson, Bergur V.
    Jongs, Niels
    Chertow, Glenn M.
    Greene, Tom
    Hou, Fan Fan
    McMurray, John J. V.
    Pecoits-Filho, Roberto
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, C. David
    Umanath, Kausik
    Langkilde, Anna Maria
    Heerspink, Hiddo J. L.
    KIDNEY INTERNATIONAL, 2021, 100 (01) : 215 - 224
  • [30] Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease A Health-Economic Analysis of DAPA-CKD
    McEwan, Phil
    Darlington, Oliver
    Miller, Ryan
    McMurray, John J. V.
    Wheeler, David. C. C.
    Heerspink, Hiddo J. L.
    Briggs, Andrew
    Bergenheim, Klas
    Sanchez, Juan Jose Garcia
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 17 (12): : 1730 - 1741
12345